Search





Search





Markets
/
Stocks
/
nasdaq-lsta
/

Lisata Therapeutics Inc

LSTA

Add to Watchlist

3.170USD

+0.090+2.92%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

28.87MMarket Cap

LossP/E TTM



Lisata Therapeutics Inc

3.170

+0.090+2.92%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lisata Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Lisata Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 113 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.33.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lisata Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

113 / 382

Overall Ranking

239 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lisata Therapeutics Inc Highlights

StrengthsRisks

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Growing

The company is in a growing phase, with the latest annual income totaling USD 170.00K.

Undervalued

The company’s latest PE is -1.71, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 994.59K shares, increasing 19.05% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 123.72K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.333

Target Price

+267.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Lisata Therapeutics Inc is 5.79, ranking 312 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.79

Change



Financials

9.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

2.29

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lisata Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Lisata Therapeutics Inc is 8.45, ranking 43 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.71, which is -87.31% below the recent high of -0.22 and -55.80% above the recent low of -2.66.

Score

Industry at a Glance

Previous score

8.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Lisata Therapeutics Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 15.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.333

Target Price

+267.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Lisata Therapeutics Inc

LSTA

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Lisata Therapeutics Inc is 7.38, ranking 71 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.50 and the support level at 2.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.15

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.097

Neutral

RSI(14)

37.235

Neutral

STOCH(KDJ)(9,3,3)

33.987

Neutral

ATR(14)

0.154

High Vlolatility

CCI(14)

-90.733

Neutral

Williams %R

63.415

Sell

TRIX(12,20)

-1.224

Sell

StochRSI(14)

79.445

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.210

Sell

MA10

3.231

Sell

MA20

3.203

Sell

MA50

4.176

Sell

MA100

3.849

Sell

MA200

3.091

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Lisata Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.92%, representing a quarter-over-quarter increase of 34.03%. The largest institutional shareholder is James Simons, holding a total of 123.72K shares, representing 1.36% of shares outstanding, with 13.72% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ruoslahti (Erkki)

1.10M

-6.62%

Mazzo (David J)

304.59K

+15.08%

Renaissance Technologies LLC

Star Investors

123.72K

+6.08%

Buck (Kristen K)

93.46K

+17.13%

Azab (Mohammad)

82.74K

+58.26%

Klosk (Steven Mark)

80.03K

+61.44%

Brown (Gregory B)

79.87K

+61.63%

Flowers (Cynthia Louise)

79.66K

+61.90%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lisata Therapeutics Inc is 2.31, ranking 224 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.